Acorda Therapeutics, Inc. (Nasdaq: ACOR) 234% HIGHER; Announced positive results from its Phase 3 clinical trial of Fampridine-SR on walking ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE